Study Summary
This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of anti-CLL1 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CLL1 positive relapsed or refractory acute myeloid leukemia.
Want to learn more about this trial?
Request More InfoInterventions
anti-CLL1 CARTBIOLOGICAL
Split intravenous infusion of anti-CLL1 CAR T cells \[dose escalating infusion of (5-20)x10\^6 anti-CLL1 CAR T cells/kg\].
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The First Affiliated Hospital of Soochow University | Suzhou | Jiangsu | China |